Michael P. Hill - Concepedia

Author

Michael P. Hill

University of Manchester

Also Known As

M Hill, M P Hill, M. Hill, M. P. Hill, M.P. Hill, Michael Hill, Michael P Hill, Michael P. Hill

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

University of Manchester Motac Neuroscience (United Kingdom)Atuka (Canada)Toronto Western Hospital University Health Network

About

Michael P. Hill is an author at University of Manchester specializing in neuroscience, medicine, and neuropharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	15	1.1K
2	Neuroscience	15	15	1.1K
3	Neurology	11	11	910
4	Social Sciences	6	6	475
5	Health Sciences	1	1	28

Michael P. Hill

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study Katarzyna Sieradzan, Susan H. Fox, Michael P. Hill, Neurology	2001	336
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease Vincenzo Di Marzo, Michael P. Hill, Tiziana Bisogno, The FASEB Journal	2000	304
A role for endocannabinoids in the generation of parkinsonism and levodopa‐induced dyskinesia in MPTP‐lesioned non‐human primate models of Parkinson's disease Mario van der Stelt, Susan H. Fox, Michael P. Hill, The FASEB Journal NeurotransmitterCannabinoid PharmacologySocial SciencesMotor ActivityNeurology	2005	199
Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease Susan H. Fox, Brian Henry, Michael P. Hill, Movement Disorders	2002	162
Fipamezole (JP‐1730) is a potent α<sub>2</sub> adrenergic receptor antagonist that reduces levodopa‐induced dyskinesia in the MPTP‐lesioned primate model of Parkinson's disease Juha‐Matti Savola, Michael P. Hill, Mia Engström, Movement Disorders Psychotropic MedicationPharmacotherapyLevodopa‐induced DyskinesiaAdrenergic Receptor AntagonistNeurology	2003	155
Sleep disorders in Parkinson's disease: The contribution of the MPTP non-human primate model Quentin Barraud, Virginie Lambrecq, Claude Forni, Experimental Neurology Sleep DisordersSleepSleep DisorderParkinson DiseaseNeuropharmacology	2009	141
Antiparkinsonian Actions of Ifenprodil in the MPTP-Lesioned Marmoset Model of Parkinson's Disease Joanne E. Nash, Susan H. Fox, Bill Henry, Experimental Neurology MedicineAntiparkinsonian ActionsAutophagyExperimental NeuropathologyNeuropharmacology	2000	123
Antiparkinsonian Actions of Blockade of NR2B-Containing NMDA Receptors in the Reserpine-Treated Rat Joanne E. Nash, Michael P. Hill, Jonathan M. Brotchie Experimental Neurology NeurophysiologyMedicineAntiparkinsonian ActionsNeurotransmitterNeuropharmacology	1999	80
Metabotropic glutamate receptor agonists inhibit endogenous glutamate release from rat striatal synaptosomes Stephen J. East, Michael P. Hill, Jonathan M. Brotchie European Journal of Pharmacology Synaptic PlasticityEndogenous Glutamate ReleaseNeurophysiologyMedicineSynaptic Transmission	1995	78
Levetiracetam Potentiates the Antidyskinetic Action of Amantadine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson’s Disease Michael P. Hill, Paula Ravenscroft, Erwan Bézard, Journal of Pharmacology and Experimental Therapeutics	2004	74

Page 1